{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:19:39Z","timestamp":1793272779553,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clgc.2019.11.002","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T23:11:29Z","timestamp":1585437089000},"page":"258-267.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment"],"prefix":"10.1016","volume":"18","author":[{"given":"Ravi A.","family":"Madan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Karzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody J.","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Cordes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy H.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Eisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Dahut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-5613","authenticated-orcid":false,"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.11.002_bib1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.002_bib2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.002_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.002_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.002_bib5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.002_bib6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14737140.2018.1503954","article-title":"Apalutamide for the treatment of prostate cancer","volume":"18","author":"Rathkopf","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clgc.2019.11.002_bib7","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib8","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.clgc.2019.11.002_bib10","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdz397","article-title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","volume":"30","author":"Small","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2019.11.002_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2019.11.002_bib13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.11.002_bib14","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib15","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.11.002_bib16","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","article-title":"Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer","volume":"2","author":"Wyatt","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-14-3080","article-title":"Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2019.11.002_bib18","doi-asserted-by":"crossref","first-page":"R175","DOI":"10.1530\/ERC-10-0339","article-title":"Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy","volume":"18","author":"Cai","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clgc.2019.11.002_bib19","first-page":"1","article-title":"Resistance to novel antiandrogen therapies in metastatic castration-resistant prostate cancer","volume":"10","author":"Boudadi","year":"2016","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib20","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A\u00a0clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2019.11.002_bib21","doi-asserted-by":"crossref","first-page":"e00499","DOI":"10.7554\/eLife.00499","article-title":"Overcoming mutation-based resistance to antiandrogens with rational drug design","volume":"2","author":"Balbas","year":"2013","journal-title":"Elife"},{"key":"10.1016\/j.clgc.2019.11.002_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.prnil.2016.05.001","article-title":"New drugs in prostate cancer","volume":"4","author":"Yoo","year":"2016","journal-title":"Prostate Int"},{"key":"10.1016\/j.clgc.2019.11.002_bib23","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.bmcl.2014.04.024","article-title":"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors","volume":"24","author":"Rafferty","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.clgc.2019.11.002_bib24","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1172\/JCI87328","article-title":"Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer","volume":"127","author":"Norris","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clgc.2019.11.002_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/1535-7163.MCT-14-0521","article-title":"Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer","volume":"14","author":"Toren","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2019.11.002_bib26","doi-asserted-by":"crossref","first-page":"35354","DOI":"10.1038\/srep35354","article-title":"Targeting of CYP17A1 lyase by VT-464 Inhibits adrenal and intratumoral androgen biosynthesis and tumor growth of castration resistant prostate cancer","volume":"6","author":"Maity","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2019.11.002_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eururo.2014.10.014","article-title":"Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study","volume":"68","author":"Caffo","year":"2015","journal-title":"Eur Urol"},{"issue":"suppl 7","key":"10.1016\/j.clgc.2019.11.002_bib28","article-title":"The oral CYP17-lyase (L) inhibitor VT-464 in patients with CRPC","volume":"33","author":"de Bono","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib29","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-18-0564","article-title":"Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in men with castration-resistant prostate cancer","volume":"24","author":"Gupta","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.11.002_bib30","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1\u2014update and clarification: from the RECIST Committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.11.002_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10549-018-4813-z","article-title":"Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer","volume":"171","author":"Bardia","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clgc.2019.11.002_bib33","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2019.11.002_bib34","first-page":"563","article-title":"Addison disease: early detection and treatment principles","volume":"89","author":"Michels","year":"2014","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clgc.2019.11.002_bib35","volume":"2 Vols","year":"2011"},{"key":"10.1016\/j.clgc.2019.11.002_bib36","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2017.76.4381","article-title":"Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer","volume":"36","author":"Szmulewitz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-019-03908-0","article-title":"A\u00a0population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced\/metastatic castration-resistant prostate cancer or breast cancer","volume":"84","author":"Peer","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2019.11.002_bib38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40262-015-0271-5","article-title":"Clinical pharmacokinetic studies of enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clgc.2019.11.002_bib39","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib40","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2019.11.002_bib41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.phrs.2016.10.001","article-title":"Androgen receptor variation affects prostate cancer progression and drug resistance","volume":"114","author":"McCrea","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clgc.2019.11.002_bib42","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2019.11.002_bib43","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.23658","article-title":"Cognitive effects of hormone therapy in men with prostate cancer: a review","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2019.11.002_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2019.11.002_bib45","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/1078-0432.CCR-10-2955","article-title":"Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer","volume":"17","author":"Rathkopf","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319303532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319303532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:33:33Z","timestamp":1761564813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319303532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1558767319303532"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.11.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}